Cite
HARVARD Citation
Sandhu, S. et al. (2023). Phase 1b study of cobimetinib plus atezolizumab in patients with advanced BRAFV600 wild-type melanoma progressing on prior anti–programmed death-1 therapy. European journal of cancer. pp. 180-190. [Online].